Repository logo
  • English
  • 中文
Log In
Have you forgotten your password?
  1. Home
  2. College of Medicine / 醫學院
  3. School of Medicine / 醫學系
  4. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
 
  • Details

Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma

Journal
New England Journal of Medicine
Journal Volume
382
Journal Issue
20
Pages
1894-1905
Date Issued
2020
Author(s)
Finn R.S.
Qin S.
Ikeda M.
Galle P.R.
Ducreux M.
Kim T.-Y.
Kudo M.
Breder V.
Merle P.
Kaseb A.O.
Li D.
Verret W.
Xu D.-Z.
Hernandez S.
Liu J.
Huang C.
Mulla S.
Wang Y.
Lim H.Y.
Zhu A.X.
ANN-LII CHENG  
IMbrave150 Investigators
DOI
10.1056/NEJMoa1915745
URI
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85084626971&doi=10.1056%2fNEJMoa1915745&partnerID=40&md5=81f119462a795baa3be9b4190b08d9a4
https://scholars.lib.ntu.edu.tw/handle/123456789/580027
Abstract
BACKGROUND The combination of atezolizumab and bevacizumab showed encouraging antitumor activity and safety in a phase 1b trial involving patients with unresectable hepatocellular carcinoma. METHODS In a global, openlabel, phase 3 trial, patients with unresectable hepatocellular carcinoma who had not previously received systemic treatment were randomly assigned in a 2:1 ratio to receive either atezolizumab plus bevacizumab or sorafenib until unacceptable toxic effects occurred or there was a loss of clinical benefit. The coprimary end points were overall survival and progressionfree survival in the intentiontotreat population, as assessed at an independent review facility according to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1). RESULTS The intentiontotreat population included 336 patients in the atezolizumab–bevacizumab group and 165 patients in the sorafenib group. At the time of the primary analysis (August 29, 2019), the hazard ratio for death with atezolizumab–bevacizumab as compared with sorafenib was 0.58 (95% confidence interval [CI], 0.42 to 0.79; P<0.001). Overall survival at 12 months was 67.2% (95% CI, 61.3 to 73.1) with atezolizumab–bevacizumab and 54.6% (95% CI, 45.2 to 64.0) with sorafenib. Median progressionfree survival was 6.8 months (95% CI, 5.7 to 8.3) and 4.3 months (95% CI, 4.0 to 5.6) in the respective groups (hazard ratio for disease progression or death, 0.59; 95% CI, 0.47 to 0.76; P<0.001). Grade 3 or 4 adverse events occurred in 56.5% of 329 patients who received at least one dose of atezolizumab–bevacizumab and in 55.1% of 156 patients who received at least one dose of sorafenib. Grade 3 or 4 hypertension occurred in 15.2% of patients in the atezolizumab–bevacizumab group; however, other highgrade toxic effects were infrequent. CONCLUSIONS In patients with unresectable hepatocellular carcinoma, atezolizumab combined with bevacizumab resulted in better overall and progressionfree survival outcomes than sorafenib. Copyright ? 2020 Massachusetts Medical Society.
SDGs

[SDGs]SDG3

Other Subjects
atezolizumab; bevacizumab; sorafenib; antineoplastic agent; atezolizumab; bevacizumab; monoclonal antibody; programmed death 1 receptor; abdominal pain; adult; aged; alopecia; Article; asthenia; body weight loss; cancer combination chemotherapy; cancer patient; cancer survival; confidence interval; constipation; controlled study; coughing; decreased appetite; diarrhea; disease course; drug efficacy; drug eruption; drug fatality; drug fever; drug safety; drug withdrawal; empyema; epistaxis; esophagus hemorrhage; esophagus varices; fatigue; female; gastrointestinal hemorrhage; hand foot syndrome; hazard ratio; heart arrest; heart failure; hemoperitoneum; hepatitis E; human; hyperbilirubinemia; hypertension; hypertransaminasemia; infusion related reaction; injection site reaction; intention to treat analysis; liver cell carcinoma; liver cirrhosis; liver dysfunction; liver injury; major clinical study; male; multicenter study; multiple organ failure; nausea; overall survival; phase 3 clinical trial; pneumonia; priority journal; progression free survival; proteinuria; pruritus; randomized controlled trial; respiratory distress; response evaluation criteria in solid tumors; sepsis; side effect; stomach perforation; subarachnoid hemorrhage; thrombocytopenia; treatment response; clinical trial; Kaplan Meier method; liver cell carcinoma; liver tumor; middle aged; quality of life; survival analysis; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Hepatocellular; Female; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Programmed Cell Death 1 Receptor; Quality of Life; Survival Analysis
Publisher
Massachussetts Medical Society
Type
journal article

臺大位居世界頂尖大學之列,為永久珍藏及向國際展現本校豐碩的研究成果及學術能量,圖書館整合機構典藏(NTUR)與學術庫(AH)不同功能平台,成為臺大學術典藏NTU scholars。期能整合研究能量、促進交流合作、保存學術產出、推廣研究成果。

To permanently archive and promote researcher profiles and scholarly works, Library integrates the services of “NTU Repository” with “Academic Hub” to form NTU Scholars.

總館學科館員 (Main Library)
醫學圖書館學科館員 (Medical Library)
社會科學院辜振甫紀念圖書館學科館員 (Social Sciences Library)

開放取用是從使用者角度提升資訊取用性的社會運動,應用在學術研究上是透過將研究著作公開供使用者自由取閱,以促進學術傳播及因應期刊訂購費用逐年攀升。同時可加速研究發展、提升研究影響力,NTU Scholars即為本校的開放取用典藏(OA Archive)平台。(點選深入了解OA)

  • 請確認所上傳的全文是原創的內容,若該文件包含部分內容的版權非匯入者所有,或由第三方贊助與合作完成,請確認該版權所有者及第三方同意提供此授權。
    Please represent that the submission is your original work, and that you have the right to grant the rights to upload.
  • 若欲上傳已出版的全文電子檔,可使用Open policy finder網站查詢,以確認出版單位之版權政策。
    Please use Open policy finder to find a summary of permissions that are normally given as part of each publisher's copyright transfer agreement.
  • 網站簡介 (Quickstart Guide)
  • 使用手冊 (Instruction Manual)
  • 線上預約服務 (Booking Service)
  • 方案一:臺灣大學計算機中心帳號登入
    (With C&INC Email Account)
  • 方案二:ORCID帳號登入 (With ORCID)
  • 方案一:定期更新ORCID者,以ID匯入 (Search for identifier (ORCID))
  • 方案二:自行建檔 (Default mode Submission)
  • 方案三:學科館員協助匯入 (Email worklist to subject librarians)

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science